Sarver Vrooman Wealth Advisors Makes New $72,000 Investment in Exelixis, Inc. $EXEL

Sarver Vrooman Wealth Advisors acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,629 shares of the biotechnology company’s stock, valued at approximately $72,000.

Other hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in Exelixis by 32.2% during the 1st quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 1,328 shares during the last quarter. Park Avenue Securities LLC boosted its holdings in Exelixis by 10.6% during the 1st quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company’s stock worth $272,000 after acquiring an additional 707 shares during the last quarter. Belpointe Asset Management LLC purchased a new position in Exelixis during the 1st quarter worth $572,000. Envestnet Asset Management Inc. boosted its holdings in Exelixis by 23.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company’s stock worth $9,159,000 after acquiring an additional 47,845 shares during the last quarter. Finally, Intech Investment Management LLC boosted its holdings in Exelixis by 46.4% during the 1st quarter. Intech Investment Management LLC now owns 392,022 shares of the biotechnology company’s stock worth $14,473,000 after acquiring an additional 124,297 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of analyst reports. Morgan Stanley cut their price objective on shares of Exelixis from $48.00 to $46.00 and set an “overweight” rating on the stock in a report on Tuesday, July 29th. Guggenheim reiterated a “buy” rating and set a $45.00 target price on shares of Exelixis in a research note on Tuesday, July 29th. Zacks Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 26th. Royal Bank Of Canada lowered their target price on Exelixis from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 29th. Finally, Benchmark reiterated a “neutral” rating on shares of Exelixis in a research note on Monday, June 23rd. Thirteen investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $44.06.

Exelixis Stock Performance

Shares of Exelixis stock opened at $39.01 on Tuesday. Exelixis, Inc. has a 52-week low of $25.17 and a 52-week high of $49.62. The stock’s 50-day simple moving average is $39.87 and its 200 day simple moving average is $39.66. The stock has a market capitalization of $10.50 billion, a P/E ratio of 18.75, a P/E/G ratio of 0.81 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business had revenue of $568.26 million for the quarter, compared to analysts’ expectations of $574.36 million. During the same period in the previous year, the business posted $0.84 EPS. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. Equities research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.